Zobrazeno 1 - 10
of 444
pro vyhledávání: '"Robert H. Vonderheide"'
Autor:
Jacob E. Till, Lee McDaniel, Changgee Chang, Qi Long, Shannon M. Pfeiffer, Jaclyn P. Lyman, Lacey J. Padrón, Deena M. Maurer, Jia Xin Yu, Christine N. Spencer, Pier Federico Gherardini, Diane M. Da Silva, Theresa M. LaVallee, Charles Abbott, Richard O. Chen, Sean M. Boyle, Neha Bhagwat, Samuele Cannas, Hersh Sagreiya, Wenrui Li, Stephanie S. Yee, Aseel Abdalla, Zhuoyang Wang, Melinda Yin, Dominique Ballinger, Paul Wissel, Jennifer Eads, Thomas Karasic, Charles Schneider, Peter O’Dwyer, Ursina Teitelbaum, Kim A. Reiss, Osama E. Rahma, George A. Fisher, Andrew H. Ko, Zev A. Wainberg, Robert A. Wolff, Eileen M. O’Reilly, Mark H. O’Hara, Christopher R. Cabanski, Robert H. Vonderheide, Erica L. Carpenter
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-12 (2024)
Abstract While high circulating tumor DNA (ctDNA) levels are associated with poor survival for multiple cancers, variant-specific differences in the association of ctDNA levels and survival have not been examined. Here we investigate KRAS ctDNA (ctKR
Externí odkaz:
https://doaj.org/article/4f9cd688d606493b979047418e6f71a0
Autor:
Il-Kyu Kim, Mark S. Diamond, Salina Yuan, Samantha B. Kemp, Benjamin M. Kahn, Qinglan Li, Jeffrey H. Lin, Jinyang Li, Robert J. Norgard, Stacy K. Thomas, Maria Merolle, Takeshi Katsuda, John W. Tobias, Timour Baslan, Katerina Politi, Robert H. Vonderheide, Ben Z. Stanger
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-16 (2024)
Abstract Acquired resistance to immunotherapy remains a critical yet incompletely understood biological mechanism. Here, using a mouse model of pancreatic ductal adenocarcinoma (PDAC) to study tumor relapse following immunotherapy-induced responses,
Externí odkaz:
https://doaj.org/article/96e408eb89f447649478a14b903b0f6a
Autor:
Burcu Gurun, Wesley Horton, Dhaarini Murugan, Biqing Zhu, Patrick Leyshock, Sushil Kumar, Katelyn T. Byrne, Robert H. Vonderheide, Adam A. Margolin, Motomi Mori, Paul T. Spellman, Lisa M. Coussens, Terence P. Speed
Publikováno v:
BMC Genomics, Vol 24, Iss 1, Pp 1-13 (2023)
Abstract T cell receptor repertoires can be profiled using next generation sequencing (NGS) to measure and monitor adaptive dynamical changes in response to disease and other perturbations. Genomic DNA-based bulk sequencing is cost-effective but nece
Externí odkaz:
https://doaj.org/article/f072a81ae5e44edd9681ef3c1accf20e
Autor:
Adham S. Bear, Tatiana Blanchard, Joseph Cesare, Michael J. Ford, Lee P. Richman, Chong Xu, Miren L. Baroja, Sarah McCuaig, Christina Costeas, Khatuna Gabunia, John Scholler, Avery D. Posey, Mark H. O’Hara, Anze Smole, Daniel J. Powell, Benjamin A. Garcia, Robert H. Vonderheide, Gerald P. Linette, Beatriz M. Carreno
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-16 (2021)
KRAS is commonly mutated at codon 12 in several cancer types, offering a unique opportunity for the development of neoantigen-targeted immunotherapy. Here the authors present a pipeline for the prediction, identification and validation of HLA class-I
Externí odkaz:
https://doaj.org/article/5c32458bd77b40989a4cd89c57021223
Autor:
Fan Yang, Zhenqiang He, Hao Duan, Duo Zhang, Juehui Li, Huijuan Yang, Jay F. Dorsey, Wei Zou, S. Ali Nabavizadeh, Stephen J. Bagley, Kalil Abdullah, Steven Brem, Lin Zhang, Xiaowei Xu, Katelyn T. Byrne, Robert H. Vonderheide, Yanqing Gong, Yi Fan
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-15 (2021)
Glioblastomas are generally resistant to treatment with immune checkpoint inhibitors. Here the authors show that IL6 blockade, in combination with a CD40 agonist, overcomes macrophage-mediated immunosuppression and sensitizes glioblastoma to immune c
Externí odkaz:
https://doaj.org/article/b5c127f1aaa240298e7d6cf386dcde4f
Autor:
Amit Maity, Rosemarie Mick, Ramesh Rengan, Tara C. Mitchell, Ravi K. Amaravadi, Lynn M. Schuchter, Daniel A. Pryma, Dana M. Patsch, Alisha P. Maity, Andy J. Minn, Robert H. Vonderheide, John N. Lukens
Publikováno v:
OncoImmunology, Vol 10, Iss 1 (2021)
We conducted a phase I dose-escalation trial of radiation with ipilimumab in patients with melanoma with ≥2 metastatic lesions. Here, we report the final full clinical analysis. Patients received RT (6 or 8 Gy x 2 or 3 doses) to a single lesion fol
Externí odkaz:
https://doaj.org/article/095b996398624a97bbe6f7d9f1fa3de8
Autor:
Robert H. Vonderheide, Adham S. Bear
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
Like many tumor types, pancreatic ductal adenocarcinoma (PDAC) exhibits a rich network of tumor-derived cytokines and chemokines that drive recruitment of myeloid cells to the tumor microenvironment (TME). These cells, which include tumor-associated
Externí odkaz:
https://doaj.org/article/df56915ac00e41c5a7e766fe1adef617
Autor:
Nicole M. Aiello, David L. Bajor, Robert J. Norgard, Amine Sahmoud, Neha Bhagwat, Minh N. Pham, Toby C. Cornish, Christine A. Iacobuzio-Donahue, Robert H. Vonderheide, Ben Z. Stanger
Publikováno v:
Nature Communications, Vol 7, Iss 1, Pp 1-9 (2016)
Metastatic colonization—the growth of single metastatic cells or small lesions into gross metastases—is poorly understood. Here, the authors characterize the natural history of metastatic growth and assess the impact of chemotherapy in an autocht
Externí odkaz:
https://doaj.org/article/bf2c2323822742288d632d0fd9cd990d
Autor:
Vincenzo Bronte, Sven Brandau, Shu-Hsia Chen, Mario P. Colombo, Alan B. Frey, Tim F. Greten, Susanna Mandruzzato, Peter J. Murray, Augusto Ochoa, Suzanne Ostrand-Rosenberg, Paulo C. Rodriguez, Antonio Sica, Viktor Umansky, Robert H. Vonderheide, Dmitry I. Gabrilovich
Publikováno v:
Nature Communications, Vol 7, Iss 1, Pp 1-10 (2016)
Abstract Myeloid-derived suppressor cells (MDSCs) have emerged as major regulators of immune responses in cancer and other pathological conditions. In recent years, ample evidence supports key contributions of MDSC to tumour progression through both
Externí odkaz:
https://doaj.org/article/7c32c093ca484097b5efdfd00dee7e64
Publikováno v:
Cell Reports, Vol 15, Iss 12, Pp 2719-2732 (2016)
Cancer immunotherapies are more effective in tumors with robust T cell infiltrates, but mechanisms to convert T cell-devoid tumors with active immunosuppression to those capable of recruiting T cells remain incompletely understood. Here, using geneti
Externí odkaz:
https://doaj.org/article/74b65073c487485eaf8bbde68306e69e